{"entity":{"id":"nct07213570","kind":"trial","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of regorafenib in colorectal cancer, run by National Cancer Institute, Naples, now recruiting.","summary":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07213570 by National Cancer Institute, Naples, with a registry enrolment figure of 60 participants, started 2025-10-16 and due to reach its primary completion in 2026-10. Interventions recorded: standard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506). Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression Free Survival rate at 6 months in the two arms.. Colorectal eligibility wording from the registry: \"Histologically proven of colorectal adenocarcinoma\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07213570","url":"https://clinicaltrials.gov/study/NCT07213570"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07213570","phase":"2","setting":"Regorafenib as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Phase 2 Study","sponsor":"National Cancer Institute, Naples","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07213570/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}